For patients with both chronic kidney disease and type 2 diabetes, whether combination therapy with finerenone and empagliflozin would improve outcomes over single-drug therapy is unclear. New ...

Quick Take Video Summary from The New England Journal of Medicine — Ciprofloxacin vs. Aminoglycoside–Ciprofloxacin for Bubonic Plague ...

ESR1 mutations can emerge during first-line therapy and lead to endocrine resistance in advanced breast cancer. New research findings on switching to camizestrant after the detection of an ESR1 ...

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

“Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry ...

In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1 -mutation detection (and before disease progression) led to significantly longer progression ...

Though infant mortality has continuously been targeted by health policy agendas, policies tend to place it in an individualistic and narrow frame, failing to consider and address its structural ...

Data on treatments for bubonic plague are limited. In this open-label, randomized, controlled trial in Madagascar, ciprofloxacin monotherapy was noninferior to a standard aminoglycoside ...

In this trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ...

Plague is a high-consequence infectious disease with epidemic potential. Current treatment guidelines are based on weak evidence. We enrolled persons (excluding pregnant persons) in Madagascar who ...

The authors review available data on the benefits and risks of testosterone treatment in middle-aged and older men with moderate hypogonadism.

The author describes the scientific foundations of a clinical trial of a first-in-class small-molecule estrogen receptor degrader to treat patients with metastatic breast cancer.